Cargando…
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518252/ https://www.ncbi.nlm.nih.gov/pubmed/37580519 http://dx.doi.org/10.1038/s43018-023-00632-w |
| _version_ | 1785109471756812288 |
|---|---|
| author | Váraljai, Renáta Zimmer, Lisa Al-Matary, Yahya Kaptein, Paulien Albrecht, Lea J. Shannan, Batool Brase, Jan C. Gusenleitner, Daniel Amaral, Teresa Wyss, Nina Utikal, Jochen Flatz, Lukas Rambow, Florian Reinhardt, Hans Christian Dick, Jenny Engel, Daniel R. Horn, Susanne Ugurel, Selma Sondermann, Wiebke Livingstone, Elisabeth Sucker, Antje Paschen, Annette Zhao, Fang Placke, Jan M. Klose, Jasmin M. Fendler, Wolfgang P. Thommen, Daniela S. Helfrich, Iris Schadendorf, Dirk Roesch, Alexander |
| author_facet | Váraljai, Renáta Zimmer, Lisa Al-Matary, Yahya Kaptein, Paulien Albrecht, Lea J. Shannan, Batool Brase, Jan C. Gusenleitner, Daniel Amaral, Teresa Wyss, Nina Utikal, Jochen Flatz, Lukas Rambow, Florian Reinhardt, Hans Christian Dick, Jenny Engel, Daniel R. Horn, Susanne Ugurel, Selma Sondermann, Wiebke Livingstone, Elisabeth Sucker, Antje Paschen, Annette Zhao, Fang Placke, Jan M. Klose, Jasmin M. Fendler, Wolfgang P. Thommen, Daniela S. Helfrich, Iris Schadendorf, Dirk Roesch, Alexander |
| author_sort | Váraljai, Renáta |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10518252 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105182522023-09-26 Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma Váraljai, Renáta Zimmer, Lisa Al-Matary, Yahya Kaptein, Paulien Albrecht, Lea J. Shannan, Batool Brase, Jan C. Gusenleitner, Daniel Amaral, Teresa Wyss, Nina Utikal, Jochen Flatz, Lukas Rambow, Florian Reinhardt, Hans Christian Dick, Jenny Engel, Daniel R. Horn, Susanne Ugurel, Selma Sondermann, Wiebke Livingstone, Elisabeth Sucker, Antje Paschen, Annette Zhao, Fang Placke, Jan M. Klose, Jasmin M. Fendler, Wolfgang P. Thommen, Daniela S. Helfrich, Iris Schadendorf, Dirk Roesch, Alexander Nat Cancer Author Correction Nature Publishing Group US 2023-08-14 2023 /pmc/articles/PMC10518252/ /pubmed/37580519 http://dx.doi.org/10.1038/s43018-023-00632-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Váraljai, Renáta Zimmer, Lisa Al-Matary, Yahya Kaptein, Paulien Albrecht, Lea J. Shannan, Batool Brase, Jan C. Gusenleitner, Daniel Amaral, Teresa Wyss, Nina Utikal, Jochen Flatz, Lukas Rambow, Florian Reinhardt, Hans Christian Dick, Jenny Engel, Daniel R. Horn, Susanne Ugurel, Selma Sondermann, Wiebke Livingstone, Elisabeth Sucker, Antje Paschen, Annette Zhao, Fang Placke, Jan M. Klose, Jasmin M. Fendler, Wolfgang P. Thommen, Daniela S. Helfrich, Iris Schadendorf, Dirk Roesch, Alexander Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma |
| title | Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma |
| title_full | Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma |
| title_fullStr | Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma |
| title_full_unstemmed | Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma |
| title_short | Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma |
| title_sort | author correction: interleukin 17 signaling supports clinical benefit of dual ctla-4 and pd-1 checkpoint inhibition in melanoma |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518252/ https://www.ncbi.nlm.nih.gov/pubmed/37580519 http://dx.doi.org/10.1038/s43018-023-00632-w |
| work_keys_str_mv | AT varaljairenata authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT zimmerlisa authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT almataryyahya authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT kapteinpaulien authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT albrechtleaj authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT shannanbatool authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT brasejanc authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT gusenleitnerdaniel authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT amaralteresa authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT wyssnina authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT utikaljochen authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT flatzlukas authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT rambowflorian authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT reinhardthanschristian authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT dickjenny authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT engeldanielr authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT hornsusanne authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT ugurelselma authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT sondermannwiebke authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT livingstoneelisabeth authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT suckerantje authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT paschenannette authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT zhaofang authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT plackejanm authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT klosejasminm authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT fendlerwolfgangp authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT thommendanielas authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT helfrichiris authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT schadendorfdirk authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma AT roeschalexander authorcorrectioninterleukin17signalingsupportsclinicalbenefitofdualctla4andpd1checkpointinhibitioninmelanoma |